My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 2 111 / https://doi.org/10.3332/ecancer.2008.111

Case Report

Pegylated Liposomal Doxorubicin (PLD): enhanced skin toxicity in areas of vitiligo

Pegylated liposomal doxorubicin (PLD, Doxil, Caelyx) is widely used for the treatment of ovarian cancer. It is a stable formulation encapsulating doxorubicin in a ‘Stealth’ (i.e., pegylated) liposome with a half-life of about 72 hours. This drastically altered pharmacology confers on it a considerably lower risk of cardiotoxicity, no acute emesis, and near absence of alopecia or problems with extravasation necrosis. On the other hand, PLD's dose-limiting toxicity is cutaneous. Since the original phase I report, cutaneous toxicities reported with PLD fall into four common categories: the well known hand-foot syndrome (also called palmoplantar erythrodysesthesia, or PPE), a diffuse follicular rash, intertrigo-like eruption, and hyperpigmentation including melanotic macules.

Loading Article Metrics ... Please wait

Related articles

Review: Fertility preservation in gynaecologic cancers

Abstract | Full Article | PDF Published: 16 Jan 2018 / https://doi.org/10.3332/ecancer.2018.798

Review: Natural history of castration-resistant prostate cancer in sub-Saharan African black men: a single-centre study of Nigerian men

Abstract | Full Article | PDF Published: 16 Jan 2018 / https://doi.org/10.3332/ecancer.2018.797

Research: Healthy living and cancer: evidence from UK Biobank

Abstract | Full Article | PDF Published: 04 Jan 2018 / https://doi.org/10.3332/ecancer.2018.792

Case Report: Primary non-Hodgkin lymphoma of the prostate: a case report

Abstract | Full Article | PDF Published: 12 Dec 2017 / https://doi.org/10.3332/ecancer.2017.789

Case Report: A different surgical approach for cardiophrenic lymph node resection in advanced ovarian cancer

Abstract | Full Article | PDF Published: 16 Nov 2017 / https://doi.org/10.3332/ecancer.2017.780



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence